Advances in Anticancer Drugs and Pharmacotherapy of Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 74069
Special Issue Editors
Interests: mixed-methods; health services research; medication safety; adherence
Special Issues, Collections and Topics in MDPI journals
Interests: pharmaceutical technology; drug safety and efficacy; drug delivery; antibiotic resistance; infectious diseases; cancer biology; medicinal plants
Interests: natural products; microbial drug discovery; molecular oncology; ethnopharmacology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The pharmacotherapy of cancer has experienced some encouraging novel developments. A new armamentarium of anticancer drugs and their delivery have led to improvements not only in efficacy and safety profiles but also the quality of life both pre and post treatment.
The regulatory approval of several new targeted immunotherapies indicates their success in clinical trials for treating multiple types of cancer. Using a targeted immunotherapy approach, oncologists can firstly screen for protein or genetic abnormalities in a patient’s tumor and then match those with appropriate immunotherapies. Immunotherapy boosts the body’s immune system to attack cancer cells through applications of CAR T-cell therapy, immune checkpoint inhibitors, monoclonal antibodies, treatment vaccines, and immune system modulators.
In terms of drug delivery systems, the use of innovative chemotherapy delivery systems, such as pressurized intraperitoneal aerosol chemotherapy (PIPAC), has significantly reduced the severity of the side effects of systematically delivered chemotherapy. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique delivering normothermic chemotherapy into the abdominal cavity as an aerosol under pressure. Early stage trials involved administering intraperitoneal chemotherapy to multiple areas of metastasis in the abdominal area. The involved tumors normally consist of small nodules that have proliferated to such a widespread extent that they are challenging to treat using surgical incision. Likewise, conventional intravenous chemotherapy is inferior when compared with PIPAC, which applies the same standard technique used in diagnostic laparoscopy. Such direct delivery of anticancer drugs into the abdomen via a nebulizer pen, channeling an aerosolized form of chemotherapy deep into the abdominal crevices, ensures that residual drugs are subsequently removed.
This Special Issue of Cancers will cover theoretical and applied aspects of cancer drug discovery, formulation, product development, and clinical practices. Submissions presenting research related to chemical identification, in vitro/in vivo/in silico evaluation of anticancer agents, including natural products, or complementary medicine in original research and review articles are welcome.
Dr. Muhammad Abdul Hadi
Dr. Md. Sanower Hossain
Dr. Bey-Hing Goh
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
-
anticancer drugs
- hormone therapy
- immunotherapy
- complementary medicine
- dosage form design
- chemotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.